{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:10:50Z","timestamp":1794978650764,"version":"4.9.1"},"reference-count":72,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>T-cell engagers (TCEs) have recently transformed the therapeutic landscape of hematological malignancies, including relapsed or refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL). However, the variability in patient responses underscores the need for a deeper mechanistic understanding of the factors driving efficacy. Immune cell composition and T-cell functional states are emerging as critical determinants of immunotherapy outcomes. Recent advances in single-cell RNA sequencing (scRNA-seq) technologies have enabled high-resolution characterization of T-cell states, revealing a spectrum from highly activated effectors to exhausted or dysfunctional subsets within the tumor microenvironment. In this study, we conducted longitudinal scRNA-seq analyses and functional assessments of peripheral blood immune cells (peripheral blood mononuclear cells [PBMCs]) from patients with glofitamab-treated R\/R B-NHL, achieving complete metabolic response, or with progressive metabolic disease. Our findings reveal that the maintenance of na\u00efve-like (\u201cfresher\u201d) T-cell states (particularly the fresher cytotoxic T cells) at early time points is associated with clinical efficacy. In line with molecular data, T cells from responders exhibited enhanced functional activity compared with nonresponders. Furthermore, the analysis of patient PBMCs and intratumor T cells from preclinical tumor models after consecutive glofitamab treatments revealed sustained functional activity, underscoring the long-term durability of T-cell responses. Combination of glofitamab with 4-1BB costimulation translated into increased proportions of intratumor T cells having a fresher, na\u00efve-like phenotype, ultimately leading to stronger antitumor efficacy. Taken together, our findings underscore the therapeutic relevance of fresher, na\u00efve-like T-cell states and the potential of leveraging 4-1BB costimulation to overcome TCE resistance and improve clinical responses in aggressive lymphomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016925","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:47:08Z","timestamp":1769100428000},"page":"2977-2990","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9735-2931","authenticated-orcid":false,"given":"Stephan","family":"Schmeing","sequence":"first","affiliation":[{"name":"1Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-8123","authenticated-orcid":false,"given":"Sina","family":"Nassiri","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0576-0546","authenticated-orcid":false,"given":"Gabrielle","family":"Leclercq-Cohen","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4271-2690","authenticated-orcid":false,"given":"Emilio","family":"Y\u00e1ng\u00fcez","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-8852","authenticated-orcid":false,"given":"Tamara","family":"H\u00fcsser","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4168-060X","authenticated-orcid":false,"given":"Llucia Alberti","family":"Servera","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5928-2941","authenticated-orcid":false,"given":"Ramona","family":"Schlenker","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7455-0609","authenticated-orcid":false,"given":"Johannes","family":"Sam","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-7280","authenticated-orcid":false,"given":"Christian","family":"Klein","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8206-2771","authenticated-orcid":false,"given":"Pablo","family":"Uma\u00f1a","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-696X","authenticated-orcid":false,"given":"Sylvia","family":"Herter","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6311-2833","authenticated-orcid":false,"given":"Alessia","family":"Bottos","sequence":"additional","affiliation":[{"name":"3F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0581-9579","authenticated-orcid":false,"given":"Marina","family":"Bacac","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"7","key":"2026051211565204900_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies \u2014 BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2026051211565204900_bib2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/s43018-023-00586-z","article-title":"The expanding success of T cell-engaging bispecific antibodies","volume":"4","author":"Bargou","year":"2023","journal-title":"Nat Cancer"},{"issue":"1","key":"2026051211565204900_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2026051211565204900_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"issue":"7949","key":"2026051211565204900_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"S1","key":"2026051211565204900_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hon.3154","article-title":"The evolving therapy of DLBCL: bispecific antibodies","volume":"41","author":"Hutchings","year":"2023","journal-title":"Hematol Oncol"},{"issue":"19","key":"2026051211565204900_bib7","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1182\/bloodadvances.2022009066","article-title":"The race is on: bispecifics vs CAR T cells in B-cell lymphoma","volume":"7","author":"Gurumurthi","year":"2023","journal-title":"Blood Adv"},{"key":"2026051211565204900_bib8","doi-asserted-by":"crossref","first-page":"1168622","DOI":"10.3389\/fonc.2023.1168622","article-title":"T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions","volume":"13","author":"Russler-Germain","year":"2023","journal-title":"Front Oncol"},{"issue":"40","key":"2026051211565204900_bib9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1200\/EDBK_279043","article-title":"ADCs, BiTEs, CARs, and small molecules: a new era of targeted therapy in non-Hodgkin lymphoma","volume":"40","author":"Abramson","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"2026051211565204900_bib10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026051211565204900_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11864-021-00925-1","article-title":"Bispecific antibodies for non-Hodgkin lymphoma treatment","volume":"23","author":"Bock","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"2026051211565204900_bib12","doi-asserted-by":"crossref","first-page":"909008","DOI":"10.3389\/fimmu.2022.909008","article-title":"Role of bispecific antibodies in relapsed\/refractory diffuse large B-cell lymphoma in the CART era","volume":"13","author":"Gonz\u00e1lez Barca","year":"2022","journal-title":"Front Immunol"},{"issue":"26","key":"2026051211565204900_bib13","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.2021014611","article-title":"T-cell\u2013redirecting bispecific antibodies in multiple myeloma: a revolution?","volume":"139","author":"Moreau","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026051211565204900_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ajh.26379","article-title":"Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update","volume":"97","author":"Lakshman","year":"2022","journal-title":"Am J Hematol"},{"issue":"10","key":"2026051211565204900_bib15","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.3324\/haematol.2020.266858","article-title":"Novel immunotherapies in multiple myeloma \u2013 chances and challenges","volume":"106","author":"Rasche","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"2026051211565204900_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"19","key":"2026051211565204900_bib17","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.3390\/jcm10194593","article-title":"Current state of the art and prospects of T cell-redirecting bispecific antibodies in multiple myeloma","volume":"10","author":"Hosny","year":"2021","journal-title":"J Clin Med"},{"issue":"12","key":"2026051211565204900_bib18","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.3390\/cancers13122853","article-title":"Bispecific T cell engagers for the treatment of multiple myeloma: achievements and challenges","volume":"13","author":"Alhallak","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"2026051211565204900_bib19","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to train your T cells: overcoming immune dysfunction in multiple myeloma","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"45","key":"2026051211565204900_bib20","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.18632\/oncotarget.27792","article-title":"T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma","volume":"11","author":"Verkleij","year":"2020","journal-title":"Oncotarget"},{"key":"2026051211565204900_bib21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","article-title":"Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions","volume":"11","author":"Caraccio","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"2026051211565204900_bib22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40265-022-01704-4","article-title":"Tebentafusp: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"issue":"8","key":"2026051211565204900_bib23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","article-title":"Tarlatamab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"issue":"19","key":"2026051211565204900_bib24","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2026051211565204900_bib25","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/bjh.20033","article-title":"In vitro comparison of CD20xCD3 biosimilar antibodies against diffuse large B-cell lymphoma (DLBCL) cell lines with different levels of expression of CD20","volume":"206","author":"Bray","year":"2025","journal-title":"Br J Haematol"},{"issue":"18","key":"2026051211565204900_bib26","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026051211565204900_bib27","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"2026051211565204900_bib28","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40265-023-01894-5","article-title":"Glofitamab: first approval","volume":"83","author":"Shirley","year":"2023","journal-title":"Drugs"},{"issue":"10466","key":"2026051211565204900_bib29","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"issue":"9","key":"2026051211565204900_bib30","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/s41591-023-02515-0","article-title":"Decoding antigen escape and multiple myeloma relapse after targeted immunotherapy","volume":"29","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"2026051211565204900_bib31","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"2026051211565204900_bib32","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"issue":"8","key":"2026051211565204900_bib33","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.2023021672","article-title":"Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell\u2013redirecting therapy","volume":"143","author":"Duell","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026051211565204900_bib34","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2023022348","article-title":"Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas","volume":"143","author":"Schuster","year":"2024","journal-title":"Blood"},{"issue":"20","key":"2026051211565204900_bib35","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2023020400","article-title":"Alternative splicing of its 5\u2032-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies","volume":"142","author":"Ang","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2026051211565204900_bib36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41408-017-0023-x","article-title":"CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment","volume":"7","author":"Mejstr\u00edkov\u00e1","year":"2017","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026051211565204900_bib37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bjh.19455","article-title":"Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high","volume":"205","author":"Grigg","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"2026051211565204900_bib38","doi-asserted-by":"crossref","first-page":"e008338","DOI":"10.1136\/jitc-2023-008338","article-title":"Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"12","author":"Brouwer-Visser","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2026051211565204900_bib39","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"2026051211565204900_bib40","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s43018-023-00637-5","article-title":"Myeloma evades T cell-engaging therapies","volume":"4","author":"Paiva","year":"2023","journal-title":"Nat Cancer"},{"issue":"1","key":"2026051211565204900_bib41","doi-asserted-by":"crossref","first-page":"210.e5-225.e5","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"2026051211565204900_bib42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","article-title":"Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing","volume":"12","author":"Li","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"2026051211565204900_bib43","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.2020006287","article-title":"Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL","volume":"137","author":"Zhao","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2026051211565204900_bib44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41591-019-0736-4","article-title":"Single-cell genomic approaches for developing the next generation of immunotherapies","volume":"26","author":"Yofe","year":"2020","journal-title":"Nat Med"},{"issue":"11","key":"2026051211565204900_bib45","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","article-title":"Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia","volume":"41","author":"Gottschlich","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2026051211565204900_bib46","doi-asserted-by":"crossref","first-page":"1265.e24-1281.e24","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"issue":"3","key":"2026051211565204900_bib47","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","article-title":"Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing","volume":"27","author":"Cohen","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"2026051211565204900_bib48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41389-023-00482-2","article-title":"Deep learning identifies a T-cell exhaustion-dependent transcriptional signature for predicting clinical outcomes and response to immune checkpoint blockade","volume":"12","author":"Zhang","year":"2023","journal-title":"Oncogenesis"},{"issue":"4","key":"2026051211565204900_bib49","doi-asserted-by":"crossref","first-page":"711.e6-725.e6","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"6","key":"2026051211565204900_bib50","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"issue":"14","key":"2026051211565204900_bib51","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-cell characteristics impact response and resistance to T-cell\u2013redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2026051211565204900_bib52","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2026051211565204900_bib53","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1182\/blood-2022-157691","article-title":"Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed\/refractory follicular lymphoma who received \u22652 prior therapies: updated results from a pivotal phase II study","volume":"140","author":"Bartlett","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2026051211565204900_bib54","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026051211565204900_bib55","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"2026051211565204900_bib56","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8+ T cell states in human cancer: insights from single-cell analysis","volume":"20","author":"van der Leun","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"33","key":"2026051211565204900_bib57","doi-asserted-by":"crossref","first-page":"e2203828120","DOI":"10.1073\/pnas.2203828120","article-title":"sccomp: robust differential composition and variability analysis for single-cell data","volume":"120","author":"Mangiola","year":"2023","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"2026051211565204900_bib58","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Br\u00f6ske","year":"2022","journal-title":"Blood Adv"},{"issue":"496","key":"2026051211565204900_bib59","doi-asserted-by":"crossref","first-page":"eaav5989","DOI":"10.1126\/scitranslmed.aav5989","article-title":"Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy","volume":"11","author":"Claus","year":"2019","journal-title":"Sci Transl Med"},{"issue":"21","key":"2026051211565204900_bib60","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2023023381","article-title":"CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy","volume":"143","author":"Sam","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2026051211565204900_bib61","doi-asserted-by":"crossref","first-page":"e010709","DOI":"10.1136\/jitc-2024-010709","article-title":"Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin\u2019s lymphoma","volume":"13","author":"Junkuhn","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026051211565204900_bib62","doi-asserted-by":"crossref","first-page":"780442","DOI":"10.3389\/fimmu.2021.780442","article-title":"T cell fitness and autologous CAR T cell therapy in haematologic malignancy","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2026051211565204900_bib63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","article-title":"Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies","volume":"14","author":"Tao","year":"2024","journal-title":"Blood Cancer J"},{"issue":"12","key":"2026051211565204900_bib64","doi-asserted-by":"crossref","first-page":"e009462","DOI":"10.1136\/jitc-2024-009462","article-title":"Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma","volume":"12","author":"Ullrich","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2026051211565204900_bib65","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2022007923","article-title":"Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed\/refractory myeloma","volume":"7","author":"Mouhieddine","year":"2023","journal-title":"Blood Adv"},{"issue":"16 suppl","key":"2026051211565204900_bib66","first-page":"7020-7020","article-title":"Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R\/R) non-Hodgkin lymphoma (NHL): results from a phase I\/II study","volume":"42","author":"Bartlett","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2026051211565204900_bib67","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/01.HS9.0000847364.49527.45","article-title":"P1124: mosunetuzumab retreatment is effective and well-tolerated in patients with relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"6","author":"Cheah","year":"2022","journal-title":"HemaSphere"},{"issue":"1","key":"2026051211565204900_bib68","doi-asserted-by":"crossref","first-page":"e0241091","DOI":"10.1371\/journal.pone.0241091","article-title":"Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFN\u03b3\/CXCL10-dependent peripheral T cell recruitment in humanized murine model","volume":"16","author":"Cremasco","year":"2021","journal-title":"PLoS ONE"},{"issue":"6","key":"2026051211565204900_bib69","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1158\/2326-6066.CIR-21-0594","article-title":"Visualizing spatial and stoichiometric barriers to bispecific T-cell engager efficacy","volume":"10","author":"You","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"2026051211565204900_bib70","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res"},{"issue":"10","key":"2026051211565204900_bib71","doi-asserted-by":"crossref","first-page":"e0141669","DOI":"10.1371\/journal.pone.0141669","article-title":"Impact of diverse immune evasion mechanisms of cancer cells on T cells engaged by EpCAM\/CD3-bispecific antibody construct AMG 110","volume":"10","author":"Deisting","year":"2015","journal-title":"PLoS ONE"},{"issue":"8","key":"2026051211565204900_bib72","doi-asserted-by":"crossref","first-page":"e0183390","DOI":"10.1371\/journal.pone.0183390","article-title":"Bispecific T cell engager (BiTE\u00ae) antibody constructs can mediate bystander tumor cell killing","volume":"12","author":"Ross","year":"2017","journal-title":"PLoS ONE"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/2977\/2515942\/blooda_adv-2025-016925-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/2977\/2515942\/blooda_adv-2025-016925-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:57:05Z","timestamp":1778601425000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/2977\/566202\/Molecular-features-of-response-and-resistance-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016925","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,4,30]]}}}